While some practitioners may feel obligated to obtain 1p/19q deletional status for all cases of infiltrating glioma, the probability of discovering this alteration in tumors that are clearly astrocytic morphologically (particularly for those demonstrating immunohistochemical evidence of TP53 and ATRX mutations) is quite low. This evidence concerns the gene TP53 and central nervous system cancer.